Breaking News Instant updates and real-time market news.

AAXN

Axon

$27.25

-0.91 (-3.23%)

, ETSY

Etsy

$21.03

-0.09 (-0.43%)

17:33
02/27/18
02/27
17:33
02/27/18
17:33

On The Fly: After Hours Movers

UP AFTER EARNINGS: Axon Enterprise (AAXN), up 15.6%... Etsy (ETSY), up 13.2%... Booking Holdings (PCLN), up 6.9%... Weight Watchers (WTW), up 6.8%... R.R. Donnelley (RRD), up 6.7%... Penumbra (PEN), up 6.4%... Air Transport Services (ATSG), up 4.8%... Camping World (CWH), up 4.1%... Veeva Systems (VEEV), up 3.9%... Express Scripts (ESRX), up 3.3%... Albemarle (ALB), up 2.2%. ALSO HIGHER: PHH Corp. (PHH), up 24.4% after it reported quarterly results and agreed to be acquired by Ocwen (OCN) for $360M... TiVo (TIVO), up 12.2% after reporting quarterly results and after it announced a plan to explore strategic alternatives... Ocwen Financial, up 11.6% after agreeing to acquire PHH. DOWN AFTER EARNINGS: Frontier Communications (FTR), down 15.4%... B&G Foods (BGS), down 12.2%... Tesaro (TSRO), down 10.6%... e.l.f. Beauty (ELF), down 8.3%... Acadia (ACAD), down 7.7%... Papa John's (PZZA), down 6.3%... Teladoc (TDOC), down 5.8%... EOG Resources (EOG), down 5.6%... Hertz (HTZ), down 3.4%. ALSO LOWER: Celgene (CELG), down 7.2% after it received a Refusal to File letter from the FDA regarding its NDA for ozanimod.

AAXN

Axon

$27.25

-0.91 (-3.23%)

ETSY

Etsy

$21.03

-0.09 (-0.43%)

PCLN

Ticker changed to BKNG

$0.00

(0.00%)

WTW

Weight Watchers

$69.83

-1.83 (-2.55%)

RRD

R.R. Donnelley

$6.98

-0.26 (-3.59%)

PEN

Penumbra

$104.30

0.15 (0.14%)

ATSG

Air Transport Services

$24.81

-0.41 (-1.63%)

CWH

Camping World

$41.29

-1.74 (-4.04%)

VEEV

Veeva

$62.07

-0.03 (-0.05%)

ESRX

Express Scripts

$78.64

1 (1.29%)

ALB

Albemarle

$111.57

1.47 (1.34%)

PHH

PHH Corp.

$8.52

-0.32 (-3.62%)

OCN

Ocwen

$3.37

-0.08 (-2.32%)

TIVO

TiVo

$13.55

-0.05 (-0.37%)

FTR

Frontier Communications

$9.24

(0.00%)

BGS

B&G Foods

$31.20

-0.8 (-2.50%)

TSRO

Tesaro

$61.55

1.78 (2.98%)

ELF

e.l.f. Beauty

$20.34

-1 (-4.69%)

ACAD

Acadia

$31.16

-1.17 (-3.62%)

PZZA

Papa John's

$56.36

-0.91 (-1.59%)

TDOC

Teladoc

$37.30

-1.25 (-3.24%)

EOG

EOG Resources

$106.94

-2.55 (-2.33%)

HTZ

Hertz

$19.26

-0.76 (-3.80%)

CELG

Celgene

$95.78

-0.71 (-0.74%)

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 05

    Mar

  • 07

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 18

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

  • 25

    Mar

  • 02

    May

  • 30

    May

AAXN Axon
$27.25

-0.91 (-3.23%)

08/10/17
JPMS
08/10/17
NO CHANGE
Target $32
JPMS
Overweight
Axon selloff yesterday overdone, says JPMorgan
JPMorgan analyst Mark Strouse views yesterday's 9% post-earnings selloff in shares of Axon as overdone. The company has "strong visibility" into gross margin improvement during the second half of 2017, Strouse tells investors in a research note. He maintains an Overweight rating on Axon with a $32 price target.
04/06/17
IMPC
04/06/17
NO CHANGE
Target $25
IMPC
In-Line
Taser shift to 'Axon' brings SaaS promise, challenges, says Imperial Capital
Imperial Capital analyst Jeff Kessler said Taser's name change to Axon is a "bold move" that reflects the company's vision of becoming a Software-as-a-Service security company, which could yield higher and faster growing recurring revenue down the line. However, the company will also have to face SaaS realities, such as significant investment, new pricing models, revised sales and marketing plans and new partner models, said Kessler, who keeps an In-Line rating and $25 price target on the shares.
11/16/17
MAXM
11/16/17
NO CHANGE
Target $4
MAXM
Buy
Digital Ally price target lowered to $4 from $9 at Maxim
Maxim analyst Brian Kinstlinger lowered his price target on Digital Ally (DGLY) to $4, saying Q3 results showed revenue remains depressed while the low $316k cash balance means the company will have to raise cash before year-end. Kinstlinger keeps his Buy rating, noting the company's strategic alternatives review as well as its patent infringement suit against Axon (AAXN) that could produce shareholder value, but says it is difficult to predict the outcome of litigation.
11/17/17
CHLM
11/17/17
NO CHANGE
Target $30
CHLM
Buy
Craig-Hallum more confident in Axon after analyst day
Craig-Hallum analyst Steven Dyer said that after attending Axon's analyst day meeting he is more confident in management's ability to drive profitable growth, noting that they highlighted not only their sales growth but their margin expansion opportunities. Dyer reiterates his Buy rating and $30 price target on Axon shares.
ETSY Etsy
$21.03

-0.09 (-0.43%)

12/20/17
KEYB
12/20/17
INITIATION
Target $26
KEYB
Overweight
Etsy initiated with an Overweight at KeyBanc
KeyBanc analyst Jason Gere started Etsy with an Overweight rating and $26 price target. The analyst says underlying double-digit secular growth, greater than 15% adjusted EBITDA margins and "visible self-help initiatives" make the company "unique" within e-commerce.
02/21/18
DADA
02/21/18
NO CHANGE
Target $26
DADA
Buy
Etsy price target raised to $26 from $20 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Etsy to $26, saying the new management is exploiting the company's business model - "one of the analyst's favorites in consumer technology". Forte cites the management's progress with the payment system as well as capitalizing on the opportunity of the holiday selling period, which should produce positive results in Q4, and carry the innovation momentum into Q1-Q2. The analyst keeps his Buy rating on Etsy.
01/12/18
MSCO
01/12/18
DOWNGRADE
Target $17
MSCO
Underweight
Etsy downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Brian Nowak downgraded Etsy to Underweight from Equal Weight, primarily citing valuation as being too expensive compared to its peers and the stock's historical average. Without evidence that the company's new management can drive faster than expected revenue growth, he believes investors may not continue to be willing to buy the stock at its current multiple, Nowak tells investors. However, given estimated cost savings from cloud migration and a lower expected tax rate, Nowak raised his price target on Etsy shares to $17 from $13.50.
01/12/18
01/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt arguing there is currently "too much uncertainty" relating to the economic impact of the company's pending News Feed changes communicated in a post last night by CEO Mark Zuckerberg. 2. Snap (SNAP) downgraded to Underperform from Market Perform at Raymond James with analyst Aaron Kessler saying Snap is largely a Chat/Message app and not a camera company as it refers to itself. 3. Etsy (ETSY) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Nowak citing valuation as being too expensive compared to its peers and the stock's historical average. 4. Comcast (CMCSA) downgraded to Buy from Action List Buy at TD Securities with analyst Vince Valentin citing recent shares strength and to make room of new Action List addition Shaw Communications (SJR), where he now sees better upside potential. 5. Electronic Arts (EA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Brian Nowak citing disappointing "Star Wars: Battlefront 2" third party data. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PCLN Ticker changed to BKNG
$0.00

(0.00%)

02/22/18
DBAB
02/22/18
NO CHANGE
Target $2045
DBAB
Hold
Priceline price target raised to $2,045 from $1,825 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Priceline to $2,045 but keeps a Hold rating on the shares ahead of the company's Q4 results. He sees investor expectations as "slightly elevated" into the print given "strong (but unreliable)" third-party data, optimism around guidance for room nights and profitability, share buybacks, and "complacency" around Google Travel risk. The analyst expects a "meaningful step up" in the pace of share buybacks in 2018 post tax reform. Walmsley, however, sees more attractive risk/reward scenarios in other large cap Internet names.
01/12/18
RHCO
01/12/18
NO CHANGE
Target $2200
RHCO
Buy
Priceline price target raised to $2,200 from $2,000 at SunTrust
SunTrust analyst Youssef Squali kept his Buy rating and raised his price target on Priceline to $2,200 as part of his "Favorite Internet Stocks; Bullish Thesis Strengthened" research note. Squali says the stock is attractive based on the company's fundamentally strong position in online travel space, adding that Priceline has deliberately sacrificed near-term outlook to position itself for sustained growth and profitability. The analyst also notes that the reduced expectations for the company do not reflect the contribution from its TV advertising and SEM/SEO investments.
02/26/18
MKMP
02/26/18
NO CHANGE
Target $1850
MKMP
Neutral
Priceline 'not attractive' ahead of earnings, says MKM Partners
MKM Partners analyst Rob Sanderson keeps his Neutral rating and $1,850 price target on Priceline ahead of tomorrow's earnings. Sanderson notes that while the stock has risen 11% since December on favorable FX conditions and the positive tax impact, the set-up for earnings is not attractive because Priceline trades at the midpoint of its post-recession valuation range and bookings growth is at all-time lows. The analyst keeps his Neutral rating on Priceline, warning that bookings could decelerate even further.
01/30/18
WELS
01/30/18
NO CHANGE
Target $1850
WELS
Market Perform
Priceline price target raised to $1850 from $1800 at Wells Fargo
Wells Fargo analyst Ken Sena raised his price target for Priceline to $1850 from $1800 after assuming "lead" coverage of the stock. The analyst kept a Market Perform rating on the shares.
WTW Weight Watchers
$69.83

-1.83 (-2.55%)

02/06/18
CHLM
02/06/18
NO CHANGE
Target $70
CHLM
Buy
Craig-Hallum sees good buying opportunity ahead of Weight Watchers event
Craig-Hallum analyst Alex Fuhrman notes that Weight Watchers announced it will webcast a global employee event on February 7. The analyst sees a "good buying opportunity" ahead of tomorrow's webcast employee event in which Weight Watchers is expected to unveil three-year goals. Fuhrman reiterates a Buy rating and $70 price target on the shares.
02/07/18
CHLM
02/07/18
NO CHANGE
Target $80
CHLM
Buy
Weight Watchers price target raised to $80 from $70 at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman raised his price target for Weight Watchers to $80 from $70, saying he sees "great" buying opportunity following ambitious 2020 revenue goal of $2B which could set up Weight Watchers for about $4.50 in EPS. The analyst reiterates a Buy rating on the shares.
02/08/18
RILY
02/08/18
NO CHANGE
Target $86
RILY
Buy
Weight Watchers price target raised to $86 from $65 at B. Riley FBR
B. Riley FBR analyst Kara Anderson raised her price target for Weight Watchers to $86 after the company laid out a strategic vision and three-year plan that included a fiscal 2020 revenue target of $2B, which the analyst notes is well above expectations. Commentary on the reception of Weight Watchers' new plan for the 2018 diet season is "very positive," the analyst adds. She keeps an Overweight rating on the shares.
01/19/18
CHLM
01/19/18
NO CHANGE
Target $70
CHLM
Buy
Weight Watchers paid length of stay increasing due to Connect, says Craig-Hallum
Craig-Hallum analyst Alex Fuhrman said Connect, Weight Watchers' social media platform, is possibly "the most important change to happen in the last 5 years" at the company and he attributes the rise of the platform as the reason that paid length of stay has just started to increase for the first time in years. The analyst, who thinks this trend is "just getting started" based on his positive view of the Connect platform, keeps a Buy rating and $70 price target on Weight Watchers shares.
RRD R.R. Donnelley
$6.98

-0.26 (-3.59%)

09/29/17
SBSH
09/29/17
DOWNGRADE
Target $14
SBSH
Sell
LSC Communications downgraded to Sell from Neutral at Citi
Citi analyst Anthony Pettinari downgraded LSC Communications (LKSD) to Sell saying the near-to-medium term organic growth targets set during the separation from R.R. Donnelley (RRD) are unlikely to be achieved. The analyst expects secular pressures to continue and sees LSC's margins falling to 9% in 2018. The stock will underperform as 2017 guidance is likely to be lowered and the 2018 outlook may disappoint, Pettinari tells investors in a research note. He cut his price target for the shares to $14 from $18.
PEN Penumbra
$104.30

0.15 (0.14%)

01/02/18
JPMS
01/02/18
DOWNGRADE
Target $101
JPMS
Neutral
Penumbra downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Penumbra to Neutral and lowered his price target for the shares to $101 from $108. The analyst thinks "it will get harder" for Penumbra to outperform Street expectations in 2018 amid incremental competition from Medtronic and Terumo. He wants to gain greater visibility into Penumbra's pipeline and the prospects for competition before recommending the shares.
01/05/18
ADAM
01/05/18
NO CHANGE
Target $113
ADAM
Buy
Penumbra weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills said the recent weakness in Penumbra has created a compelling buying opportunity. He calls Penumbra one of the top long-term small-cap growth picks as the weakness stems from a competitors' 501(k) approval, but that approval was expected. Mills reiterated his Buy rating and $113 price target on Penumbra shares.
01/18/18
ADAM
01/18/18
NO CHANGE
Target $113
ADAM
Buy
Penumbra among top innovators in med-tech, says Canaccord
Canaccord analyst Jason Mills told investors to buy Penumbra as it continues to be one of the most innovative growth companies in the med-tech space. The analyst sees a myriad of growth opportunities, ability to deliver upside to estimates, and future drivers for market expansion. Mills reiterated his Buy rating and $113 price target on Penumbra shares.
02/21/18
WBLR
02/21/18
INITIATION
WBLR
Outperform
Penumbra initiated with an Outperform at William Blair
William Blair analyst Kaila Krum started Penumbra with an Outperform rating.
ATSG Air Transport Services
$24.81

-0.41 (-1.63%)

08/17/17
SUSQ
08/17/17
INITIATION
Target $22
SUSQ
Neutral
Air Transport Services initiated with a Neutral at Susquehanna
Susquehanna analyst Christopher Stathoulopoulos with a Neutral and a $22 price target.
03/30/17
GHSC
03/30/17
INITIATION
Target $65
GHSC
Buy
Atlas Air initiated with a Buy at Seaport Global
Seaport Global analyst Kevin Sterling initiated Atlas Air (AAWW) with a Buy and a $65 price target due to its potentially expanding relationship with Amazon.com (AMZN). Atlas is in the process of ramping 20 converted Boeing 767-300 freighters with Amazon on a CMI leasing basis. Sterling said Amazon is expending its hub operating to Cincinnati/Northern Kentucky airport and which will give the company the ability to park 100 planes at any given time at the airport, and two weeks ago, Cargo Facts reported that Amazon could be in discussion with Boeing to purchase 100 or more 767 freighters. The analyst told investors Atlas and Air Transport Services (ATSG) are well positioned to benefit from Amazon's transportation network growth as both are partners in the leasing and flying of the planes.
11/07/17
SPHN
11/07/17
NO CHANGE
Target $29
SPHN
Overweight
Air Transport Services price target raised to $29 after Q3 report at Stephens
Stephens analyst Jack Atkins noted that Air Transport Services reported better than expected Q3 earnings and reiterated its FY17 adjusted EBITDA guidance, adding that he continues to view the company as uniquely positioned to benefit from the shift towards e-commerce and need for increased supply chain velocity. He raised his price target on Air Transport to $29 from $27 and keeps an Overweight rating on the shares.
01/24/18
LSCM
01/24/18
NO CHANGE
Target $18
LSCM
Buy
StarTek price target raised to $18 after Amazon deal announcement at Lake Street
Lake Street analyst Mark Argento said the opportunity to sign a large, long-term agreement with Amazon (AMZN) is a "big win" for StarTek (SRT). He believes Amazon could contribute $100M in revenue and $10M-$12M in adjusted EBITDA for StarTek in 2019. Argento also noted that Amazon has executed deals like this in the past with other small public companies - such as Plug Power (PLUG), Air Transport Services (ATSG) and Kornit Digital (KRNT) - with favorable results to both fundamentals and equity values. He raised his price target on StarTek to $18 from $13 citing the value of the deal and keeps a Buy rating on the shares.
CWH Camping World
$41.29

-1.74 (-4.04%)

11/07/17
WELS
11/07/17
NO CHANGE
Target $48
WELS
Outperform
Camping World price target raised to $48 from $37 at Wells Fargo
Wells Fargo analyst Tim Conder raised his price target for Camping World to $48 from $37 to reflect favorable Q3 pre-announcement, and ongoing company/industry fundamental strength with momentum likely carrying into 2018. The analyst reiterates an Outperform rating on the shares and says he is a buyer ahead of earnings based on relative valuation and favorable risk/reward.
01/26/18
NRCS
01/26/18
INITIATION
Target $56
NRCS
Buy
Camping World initiated with a Buy at Northcoast
Northcoast analyst Seth Woolf initiated Camping World with a Buy and $56 price target saying it is the best way to play the structural retail benefits at work in the RV space while getting 25%+ earnings growth.
02/23/18
FBCO
02/23/18
NO CHANGE
Target $49
FBCO
Outperform
Camping World price target raised to $49 from $44.93 at Credit Suisse
Credit Suisse analyst Seth Sigman raised his price target on Camping World Holdings to $49 from $44.93 ahead of the company's fourth quarter earnings next week. In a research note to investors, Sigman said he remains "constructive" on Camping World and sees a "number of opportunities," including strong new RV demand growth and lower taxes. Sigman has an Outperform rating on shares.
10/31/17
10/31/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ollie's Bargain Outlet (OLLI) initiated with an Overweight at Stephens. 2. Switch (SWCH) initiated with an Outperform at William Blair, Credit Suisse, and BMO Capital, an Overweight at JPMorgan, a Buy at BTIG, a Market Perform at Raymond James and Wells Fargo, a Neutral at Citi and Goldman Sachs, as well as a Hold at Jefferies. 3. iRadimed (IRMD) reinitiated with a Buy at Roth Capital. 4. Northstar Realty Europe (NRE) initiated with a Buy at FBR Capital. 5. Altice USA (ATUS) initiated with an Overweight at Atlantic Equities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VEEV Veeva
$62.07

-0.03 (-0.05%)

01/30/18
01/30/18
UPGRADE
Target $72

Overweight
Veeva upgraded to Overweight on margin potential at Morgan Stanley
As previously reported, Morgan Stanley analyst Stan Zlotsky upgraded Veeva to Overweight from Equal Weight, citing its underappreciated gross margin opportunity. Veeva's gross renewal rates are best-in-class and he does not expect that to change, said Zlotsky, who estimates the company can drive up its blended gross margin to 79% by FY33 from 72% today. The analyst increased his price target on Veeva shares to $72 from $69.
02/02/18
DADA
02/02/18
INITIATION
Target $75
DADA
Buy
Veeva initiated with a Buy at DA Davidson
DA Davidson analyst Rishi Jaluria initiated Veeva with a Neutral rating and a price target of $28, tagging the company as the "top pick in software" because of its "sustainable competitive advantage, multiple growth drivers, and leading balance of growth and profitability". Jaluria cites Veeva's domain expertise and established relationships with top pharmaceutical companies creating a "sustainable moat", outperforming content management platform, and the focus on fiscal discipline.
02/21/18
MSCO
02/21/18
NO CHANGE
Target $72
MSCO
Overweight
Veeva checks suggest strong Vault momentum in Q4, says Morgan Stanley
Morgan Stanley analyst Stan Zlotsky said his Q4 checks on Veeva made him incrementally more positive on the sustainability of Vault's growth entering FY19. Along with healthy underlying trends, he also sees upside to conservative FY19 estimates, said Zlotsky, who keeps an Overweight rating and $72 price target on Veeva shares ahead of the company's Q4 report next week.
01/30/18
MSCO
01/30/18
UPGRADE
MSCO
Overweight
Veeva upgraded to Overweight from Equal Weight at Morgan Stanley
ESRX Express Scripts
$78.64

1 (1.29%)

02/13/18
LEER
02/13/18
NO CHANGE
LEER
Walgreens may seek to acquire AmerisourceBergen sooner than expected, says Leerink
Leerink analyst David Larsen notes that The Wall Street Journal reported that Walgreens (WBA) has approached AmerisourceBergen (ABC) about a potential takeover. The analyst is surprised that talks of such a large transaction have surfaced so quickly following the Rite Aid (RAD) deal, but says he has always believed that Walgreens at some point would seek to acquire either Express Scripts (ESRX) or AmerisourceBergen. Given the broad-based speculation in the business press about this deal, it is possible shares of Express Scripts will trade off, Larsen contends.
02/22/18
BERN
02/22/18
NO CHANGE
BERN
Amazon to accelerate disruption in healthcare, says Bernstein
Bernstein analyst Lance Wilkes believes that disruption is coming for healthcare, and Amazon (AMZN) will be an accelerant of this disruption. Further, the analyst thinks Amazon is developing a series of business strategies for entering the healthcare market segments, and projects that Amazon will develop an online pharmacy to disrupt the existing retail pharmacy market. Overall, Wilkes sees Amazon's strategies as creating downside risks for PBMs including Express Scripts (ESRX).
02/27/18
BOFA
02/27/18
INITIATION
Target $77
BOFA
Underperform
Express Scripts reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on Express Scripts with an Underperform and $77 price target.
02/01/18
02/01/18
DOWNGRADE
Target $69

Underperform
Express Scripts downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes downgraded Express Scripts to Underperform from Market Perform, with a $69 price target, as he believes tax reform is fully price in and his original concerns on the standalone PBM model remain. Further, the analyst sees additional risks from a potential CVS (CVS)/Aetna (AET) merger and Amazon (AMZN) threats.
ALB Albemarle
$111.57

1.47 (1.34%)

02/26/18
02/26/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Albermarle (ALB) downgraded to Underweight from Equal Weight at Morgan Stanley by analyst Vincent Andrews, who cited concerns on both the lithium supply and demand side. On the lithium demand side, bulls' electric vehicle penetration rate forecasts seem "aggressive, said Andrews. He also now has material concerns on the supply side following the recent Chilean government agreement with SQM (SQM), added Andrews. SQM was also downgraded to Underweight from Equal Weight at Morgan Stanley by analyst Javier Martinez de Olcoz Cerdan. 2. Halliburton (HAL) downgraded to Neutral from Buy at BofA/Merrill by analyst Timna Tanners, who said the U.S. shale story is maturing and there are limited catalysts for shares. Tanners expects a more muted response to high oil prices given newbuiilds coming into the market in 2018. 3. Aqua America (WTR) downgraded to Market Perform from Outperform at Wells Fargo by analyst Jonathan Reeder, who cited valuation and said he prefers shares of American Water (AWK) at current levels. 4. Mattel (MAT) downgraded to Underperform from Hold at Jefferies by analyst Stephanie Wissink. The shares currently reflect an "aggressive" sales and profit recovery to 15% margins in 2020, Wissink said, however, believes industry conditions are challenging recovery assumptions. 5. Empire State Realty (ESRT) downgraded to Hold from Buy at Stifel by analyst John Guinee, who said he expects 2018 to be a "difficult year for value creation metrics" and notes his FFO estimates continue to decline. Guinee added that the Manhattan investment market is highly competitive and that he's not convinced the company will deploy the cash balance into new investments any time soon. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/18
MSCO
02/26/18
DOWNGRADE
Target $85
MSCO
Underweight
Morgan Stanley cuts Albemarle to sell with concerns on both supply and demand
As previously reported, Morgan Stanley analyst Vincent Andrews downgraded Albemarle (ALB) to Underweight, the firm's sell-equivalent rating, from Equal Weight citing his concerns on both the lithium supply and demand side. On the lithium demand side, bulls' electric vehicle penetration rate forecasts seem "aggressive, said Andrews. He also now has material concerns on the supply side following the recent Chilean government agreement with SQM (SQM), added Andrews, who lowered his price target on Albermarle to $85 from $100. Morgan Stanley analyst Javier Martinez de Olcoz Cerdan also downgraded SQM to Underweight this morning.
02/26/18
MSCO
02/26/18
DOWNGRADE
MSCO
Underweight
Albemarle downgraded to Underweight from Equal Weight at Morgan Stanley
02/26/18
02/26/18
DOWNGRADE
Target $44

Underweight
SQM downgraded to Underweight with $44 price target at Morgan Stanley
As previously reported, Morgan Stanley analyst Javier Martinez de Olcoz Cerdan downgraded SQM (SQM) to Underweight from Equal Weight as he expects lithium prices to peak in 2018 then decline by 45% by 2021 as demand growth falls "far short" of sharp supply increases. Additionally, new supply is low cost and will transfer share from the high end to the low end of the cost curve, added the analyst. While cutting his rating to Underweight, Martinez de Olcoz Cerdan also called SQM the "best-quality lithium player globally" and increased his price target on the stock to $44 from $32.50. Morgan Stanley analyst Vincent Andrews also downgraded Albemarle (ALB) to Underweight this morning, citing his concerns on both the lithium supply and demand side.
PHH PHH Corp.
$8.52

-0.32 (-3.62%)

06/20/17
WEDB
06/20/17
DOWNGRADE
WEDB
Neutral
PHH Corp. downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Henry Coffey downgraded PHH Corp to Neutral as shares have neared his $14.50 price target.
03/03/17
WEDB
03/03/17
UPGRADE
WEDB
Outperform
PHH Corp. upgraded to Outperform from Neutral at Wedbush
03/03/17
WEDB
03/03/17
UPGRADE
WEDB
Outperform
PHH Corp. upgraded on capital return outlook at Wedbush
As noted earlier, Wedbush upgraded PHH to Outperform from Neutral. Analyst Henry J. Coffey Jr. says that, following its transition to a subservicing business, the company will be able to return more capital to shareholders than the $550M it has targeted. Target to $15.50 from $17.
OCN Ocwen
$3.37

-0.08 (-2.32%)

05/02/17
05/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Underperform from Neutral at Macquarie with analyst Srini Pajjuri telling investors PC progress was disappointing versus high expectations and margin expansion will be difficult. 2. CNA Financial (CNA) downgraded to Hold from Buy at Deutsche Bank with analyst Joshua Shanker citing valuation with the stock up 56% over the past 12 months. The analyst raised his price target for the shares to $46 from $45 following CNA's first quarter results. 3. Arthur J. Gallagher (AJG) downgraded to Market Perform on valuation at Raymond James with analyst Gregory Peters citing valuation. 4. Ocwen (OCN) downgraded to Neutral on valuation at Compass Point with analyst Fred Small citing the over 40% jump in shares following the announcement of a strategic deal with New Residential (NRZ) on Monday. The analyst maintained a $3.50 price target on Ocwen shares and recommends moving to the sidelines until viability into long-term earnings power emerges. 5. Cerner (CERN) downgraded to Neutral from Buy at Hilliard Lyons with analyst Stephen Turner citing price appreciation and raised its price target to $68. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/16/17
PIPR
05/16/17
NO CHANGE
Target $18
PIPR
Overweight
New Residential target raised to $18 after CEO meeting at Piper Jaffray
Piper Jaffray analyst Kevin Barker raised his price target for New Residential Investment (NRZ) after hosting meetings with the company's CEO Michael Nierenberg. The analyst has increased confidence that the Ocwen (OCN) mortgage servicing rights deal will be "meaningfully accretive" to New Residential and provide support for a higher dividend in the future. Barker reiterates an Overweight rating on the shares.
06/20/17
WEDB
06/20/17
DOWNGRADE
WEDB
Neutral
New Residential downgraded on downward rates, regulatory worries at Wedbush
As noted earlier, before the market opened, Wedbush downgraded New Residential (NRZ) to Neutral from Outperform Analyst Jason Weaver downgraded the stock based on falling interest rates and his belief that the CFPB and Florida's attorney general could seek to sue New Residential as part of their lawsuit against Ocwen (OCN). The analyst does not expect New Residential to be hurt by any such lawsuits, but he says that they would create headline risk for the company and could delay the closing of its deal with Ocwen. Target to $16.50 from $17.
05/15/17
COMP
05/15/17
NO CHANGE
Target $7
COMP
Sell
Altisource price target cut to $7 from $14 at Compass Point
Compass Point analyst Fred Small said Altisource's (ASPS) most profitable unit, Hubzuwhich derives 85% of profits from Ocwen (OCN), and represents over 90% of Altisource's pre-tax income, is "running out of steam" as Ocwen's portfolio declines. The analyst staid there is nothing to replace the high margin business and the recently announced sub servicing deal between Ocwen and New Residential (NRZ) increases risk on Ocwen's-sourced REO sales. The analyst said allegations about Ocwen's improper servicing suggest this is the source of the problems with Altisource's REALServicing platform. Small lowered his FY17 earnings estimate to $1.21 from $1.60 and FY18 to 65c from $1.77, cut his price target to $7 from $14, and reiterates a Sell rating on shares.
TIVO TiVo
$13.55

-0.05 (-0.37%)

02/02/18
RILY
02/02/18
UPGRADE
RILY
Buy
TiVo upgraded to Buy from Neutral at B. Riley FBR (pre-open)
02/02/18
RILY
02/02/18
UPGRADE
Target $18
RILY
Buy
B. Riley FBR upgrades TiVo to Buy following 20% pullback
B. Riley FBR analyst Eric Wold upgraded TiVo (TIVO) to Buy from Neutral with an unchanged price target of $18. The analyst sees a favorable risk/reward following the 20% pullback in the shares. He sees "minimal downside risk" given expectations for weak 2018 guidance and upside scenarios to between $18 and $35 per share with a Comcast (CMCSA) license deal and return to growth. Further, Wold says he can't rule out the possibility that TiVo becomes an acquisition target.
01/18/18
JPMS
01/18/18
NO CHANGE
JPMS
Overweight
TiVo in 'great position' after expanded Google deal, says JPMorgan
JPMorgan analyst Sterling Auty says TiVo's (TIVO) expanded agreement with Google (GOOG, GOOGL) to cover the new YouTube TV puts the company in a "great position" to capitalize if subscribers leave larger pay-TV operators for skinny bundles and cord-cutting options. The analyst is "especially excited about this agreement given millennial YouTube content consumption." He keeps an Overweight rating on TiVo shares.
01/22/18
BWSF
01/22/18
INITIATION
Target $25
BWSF
Buy
TiVo initiated with a Buy at BWS Financial
BWS Financial analyst Hamed Khorsand started TiVo with a Buy rating and $25 price target. Growth from the company's new product launches, along with the cash flow from its intellectual property licenses, "creates an attractive investment story," Khorsand tells investors in a research note.
FTR Frontier Communications
$9.24

(0.00%)

11/10/17
11/10/17
DOWNGRADE
Target $4

Underperform
Frontier Communications downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst David Barden downgraded Frontier Communications to Underperform and slashed its price target to $4 from $19 due to dividend concerns. Barden said Frontier is evaluating the dividend quarter to quarter, while trying to reduce net leverage, and cannot assume with certainty that the dividends will get paid.
12/15/17
LEHM
12/15/17
INITIATION
Target $7
LEHM
Underweight
Frontier Communications initiated with an Underweight at Barclays
Barclays analyst Amir Rozwadowski started Frontier Communications with an Underweight rating and $7 price target. The analyst believes the company's dividend is at risk of being cut further over the near term.
12/13/17
MSCO
12/13/17
NO CHANGE
Target $21.6
MSCO
Overweight
Morgan Stanley says CenturyLink can outperform after industry's challenging 2017
Noting that 2017 was a challenging year for wireline telecom and that CenturyLink struggled to hit guidance for the third consecutive year, Simon Flannery still believes that the Level 3 merger is transformative and contends that CenturyLink's (CTL) valuation should ultimately diverge from legacy wireline peers such as Frontier (FTR) and Windstream (WIN) if the deal proves successful. If 2017 marks the trough in operational performance, CenturyLink is poised to outperform "meaningfully" next year and beyond, said Flannery, who trimmed his price target on the stock to $21.60 from $26 but maintains an Overweight rating on the shares.
12/15/17
12/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Simon Flannery started ViaSat (VSAT) with an Equal Weight rating and $78 price target. 2. Cantor Fitzgerald analyst Elemer Piros initiated Rigel Pharmaceuticals (RIGL) with an Overweight rating and $6 price target, sayign the company is poised to achieve FDA approval of fostamatinib for lead indication immune thrombocytopenia. 3. Exelon (EXC) analyst Paul Fremont initiated Exelon with an Underperform and $36 price target to reflect expected earnings pressure from weak forward gas and power prices and high debt. 4. Credit Suisse analyst Gregory Lewis started Ocean Rig UDW (ORIG) with an Outperform rating and $32 price target, stating that the company's restructuring wiped away $3.3B in debt. 5. Barclays analyst Amir Rozwadowski started Frontier Communications (FTR) with an Underweight rating and $7 price target, as he believes the company's dividend is at risk of being cut further over the near term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BGS B&G Foods
$31.20

-0.8 (-2.50%)

11/01/17
SPHN
11/01/17
UPGRADE
Target $39
SPHN
Overweight
B&G Foods upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Farha Aslam upgraded B&G Foods to Overweight from Equal Weight, citing the company's strong innovation, better execution and accretive acquisitions. The shares also have a "compelling" 5.7% dividend yield, added Aslam, who raised her price target on B&G to $39 from $35.
11/16/17
BREN
11/16/17
UPGRADE
BREN
Buy
B&G Foods upgraded to Buy from Hold at Berenberg
Bernenberg analyst Adam Mizrahl upgraded B&G Foods to Buy and raised its price target to $40 from $34 saying Green Giant potential is underestimated and tail brand declines are overestimates.
08/23/17
BUCK
08/23/17
UPGRADE
BUCK
Buy
B&G Foods upgraded on improved outlook at Buckingham
As noted earlier, Buckingham upgraded B&G to Buy from Neutral. Analyst Eric Larson says that the company "is becoming more consolidated, with increasing exposure to advantaged categories." He thinks this trend will cause its profits to rise over the longer term, and he says that the company's comparisons are set to become more favorable. Target $40.
08/23/17
BUCK
08/23/17
UPGRADE
BUCK
Buy
B&G Foods upgraded to Buy from Neutral at Buckingham
TSRO Tesaro
$61.55

1.78 (2.98%)

02/22/18
02/22/18
UPGRADE

Outperform
Evercore ISI upgrades Clovis, Tesaro with PARP potential 'too big to ignore'
As previously reported, Evercore ISI analyst Steven Breazzano upgraded Clovis (CLVS) and Tesaro (TSRO), both to Outperform from In Line, as he believes the stocks' valuations are now attractive on a long-term basis following their pullbacks. He views adoption of the PARP class so far as robust, particularly in ovarian cancer, and sees further upside as PARPs move up into earlier lines of therapy, combination studies, and new indications. However, Breazzano lowered his price target on Clovis shares to $72 from $73 and decreased his target on Tesaro to $88 from $121.
02/22/18
EVER
02/22/18
UPGRADE
EVER
Outperform
Tesaro upgraded to Outperform from In Line at Evercore ISI
01/18/18
FBCO
01/18/18
NO CHANGE
Target $150
FBCO
Outperform
Tesaro price target lowered to $150 from $190 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Tesaro to $150 from $190 to include lower than forecasted Zejula or Varubi sales or clinical setbacks. The analyst reiterates an Outperform rating on the shares.
02/22/18
02/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Palo Alto Networks (PANW) upgraded to Buy from Neutral at Cleveland Research with the firm saying it's channel partner checks indicate favorable revenue/billings growth in the low-20% range, versus high teens previously, and the product refresh could be a source of upside with increased hardware growth. 2. Verisk Analytics (VRSK) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Steinerman saying he believes sustainable high-single-digit organic revenue growth is "back in sight" following last night's "strong" fourth quarter results. 3. Tesaro (TSRO) upgraded to Outperform from In Line at Evercore ISI with analyst Steven Breazzano saying he believes the stocks' valuations are now attractive on a long-term basis following their pullbacks. 4. Clovis (CLVS) was upgraded to Outperform from In Line at Evercore ISI and to Outperform from Sector Perform at RBC Capital. 5. Wolverine World Wide (WWW) upgraded to Buy from Neutral at DA Davidson with analyst Andrew Burns saying the company is positioned for accelerating growth following a multi-year restructuring. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ELF e.l.f. Beauty
$20.34

-1 (-4.69%)

02/27/18
JPMS
02/27/18
NO CHANGE
Target $18
JPMS
Underweight
JPMorgan negative on e.l.f. Beauty shares into tonight's earnings
JPMorgan analyst Andrea Teixeira continues to view e.l.f. Beauty negatively into tonight's earnings report and views the stock's recent bounce back from the January 18 low of $18.56 as unwarranted. The analyst notes the shares are currently trading at 41 times her 2018 earnings estimate. The recent share rally is unjustified as the company's sell-through rate continued to decelerate, Teixeira tells investors in a pre-earnings research note. The analyst sees continued downside in e.l.f. Beauty and keeps an Underweight rating on the shares with an $18 price target.
12/15/17
12/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. RBC Capital analyst Ross MacMillan downgraded Oracle (ORCL) to Sector Perform from Outperform and lowered his price target to $51 from $53 after Q2 results. MacMillan says that while better near-term license sales prospects buffer software revenue, bigger license declines can be expected in Q4 and beyond based on the difficult comps and "maturing 12cR2 cycle". 2. JMP Securities analyst Andrew Boone downgraded Criteo (CRTO) to Market Perform from Outperform and Citi analyst Mark Kelley downgraded Criteo to Neutral, with both citing uncertainty around Apple's (AAPL) potential response to the company's workaround of the tech giant's Intelligent Tracking Prevention. 3. Stifel analyst Jim Duffy downgraded Fitbit (FIT) to Sell from Hold as he expects the company will remain unprofitable and burn cash in 2018. 4. JPMorgan analyst Andrea Teixeira downgraded e.l.f. Beauty (ELF) to Underweight, as she expects continued deterioration in sell-through rates in tracked channels to limit the company's ability to hit its 20%-plus long-term revenue growth target.5. Goldman Sachs analyst Jami Rubin removed Amgen (AMGN) from the Conviction Buy List but maintained a Buy rating on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/17
KEYB
12/20/17
INITIATION
KEYB
Sector Weight
e.l.f. Beauty initiated with a Sector Weight at KeyBanc
KeyBanc analyst Jason Gere started e.l.f. Beauty with a Sector Weight rating saying the valuation is full at current levels. The analyst prefers to wait for a better entry point.
01/12/18
DADA
01/12/18
NO CHANGE
Target $23
DADA
Buy
e.l.f. Beauty price target lowered to $23 from $26 at DA Davidson
DA Davidson analyst Linda Bolton Weiser lowered her price target on e.l.f. Beauty to $23 after the company cut its 2017 guidance and 3-year sales projections. Weiser notes that the company remains "one of the best small-cap stories in the home and personal care sector" as it gains market share and has the opportunity to grow at above-category rate, keeping her Buy rating on the stock.
ACAD Acadia
$31.16

-1.17 (-3.62%)

10/05/17
JMPS
10/05/17
NO CHANGE
Target $50
JMPS
Outperform
Acadia price target raised to $50 from $47 at JMP Securities
JMP Securities analyst Jason Butler noted that Acadia's Phase 3 HARMONY trial of pimavanserin is a relapse prevention study, which he contends optimizes the timelines and the potential for success. Butler, who increased his probability of success in the indication of dementia-related psychosis to 65% from 50%, raised his price target on Acadia shares to $50 from $47 and keeps a Outperform rating on the stock.
10/05/17
BOFA
10/05/17
NO CHANGE
Target $46
BOFA
Buy
Acadia price target raised to $46 from $40 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Acadia's price target to $46 from $40 based on Nuplazid's opportunity for further expansion and continued positive physician feedback on Nuplazid in PDP. The analyst rates Acadia a Buy.
10/05/17
LEER
10/05/17
NO CHANGE
LEER
Market Perform
Acadia Dementia Psychosis BTD a positive surprise, says Leerink
Leerink analyst Paul Matteis notes that Acadia announced the initiation of a phase III study, HARMONY, assessing pimavanserin in various dementia related psychoses. The analyst says that the breadth of the patient population in this pivotal program - previously expected to focus on Alzheimer's Disease - is a "major surprise." Meanwhile, the FDA has granted Breakthrough Therapy Designation, or BTD, to pimavanserin for dementia-related psychosis, Matteis points out, adding that FDA feedback awarding breakthrough designation and allowing for a single pivotal study is encouraging. Moreover, the analyst says that if the study succeeds, the addressable population could be very large. The analyst reiterates a Market Perform rating on the shares.
11/06/17
LEER
11/06/17
NO CHANGE
Target $35
LEER
Market Perform
Data suggests Acadia pivotal DRP program is high risk, says Leerink
Following full data from Acadia's phase 2 study of pimavanserin in Alzheimer's Disease Psychosis patients at the Clinical Trials on Alzheimer's Disease, Leerink analyst Paul Matteis says his cautious view on the company's phase 3 dementia related psychosis program remains as the statistically significant benefit for pimavanserin seen at the primary endpoint of 6 weeks was in his view helped considerably by a temporary regression in placebo response, this dynamic was also the case in a featured, more severe subgroup, and dementia related psychosis is a chronic condition, and for any new medication a sustained clinical benefit will be important. He reiterates a Market Perform rating and $35 price target on the shares.
PZZA Papa John's
$56.36

-0.91 (-1.59%)

12/22/17
NOMU
12/22/17
NO CHANGE
Target $58
NOMU
Neutral
Papa John's price target lowered to $58 from $65 at Nomura Instinet
Nomura Instinet analyst Mark Kalinowski lowered his price target for Papa John's International to $58 saying the CEO change suggests a "rough" Q4 for the company following adverse media attention. To reflect "weakened momentum in the business," the analyst cut his 2018 earnings per share estimate to $2.75 from $3.00 and keeps a Neutral rating on Papa John's.
12/18/17
12/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Twitter (TWTR) initiated with a Buy at Summit Redstone. 2. Insteel (IIIN) initiated with a Buy at Sidoti. 3. Tiffany (TIF) initiated with a Neutral at JPMorgan. 4. Delphi Technologies (DLPH) initiated with a Buy at Jefferies. 5. Domino's Pizza (DPZ) initiated with a Buy at Deutsche Bank, while Papa John's and Wingstop (WING) were initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/27/18
OPCO
02/27/18
NO CHANGE
Target $75
OPCO
Outperform
Papa John's a more logical target for Restaurant Brands, says Oppenheimer
Oppenheimer analyst Brian Bittner says that while Domino's Pizza (DPZ) has been the center of speculation, his analysis suggests Papa John's (PZZA) represents the most logical target for Restaurant Brands (QSR). The analyst points out that Domino's Pizza larger size and valuation would require a major equity raise whereas Papa John's could be fully-funded internally by cash and pro-forma leverage. Domino's Pizza fundamentals are best-in-class, but Papa John's anatomy better fits Restaurant Brands' deal characteristics, he contends. Bittner reiterates an Outperform rating and $75 price target on Restaurant Brands' shares.
12/18/17
DBAB
12/18/17
INITIATION
Target $63
DBAB
Hold
Papa John's initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Brett Levy started Papa John's with a Hold rating and $63 price target. The analyst finds the shares fairly valued given the company's "sluggish and less inspiring" recent results.
TDOC Teladoc
$37.30

-1.25 (-3.24%)

02/09/18
PIPR
02/09/18
NO CHANGE
PIPR
Teladoc well positioned in telehealth, says Piper Jaffray
Piper Jaffray analyst Sean Wieland reiterated an Overweight rating and $46 price target, saying the approval of the budget containing the CHRONIC Care Act was a positive catalyst for the telehealth industry, and that companies like Teladoc and InTouch were well positioned to gain.
01/31/18
ADAM
01/31/18
NO CHANGE
Target $43
ADAM
Buy
Teladoc well positioned to meet or exceed estimates, says Canaccord
Canaccord analyst Richard Close believes Teladoc is well positioned to meet or exceed earnings estimates. Close reiterated his Buy rating and raised his price target to $43 from $42 on Teladoc shares, as he believes the long-term growth opportunity is massive, with a number of legislative efforts underway to drive adoption.
01/26/18
JEFF
01/26/18
INITIATION
Target $40
JEFF
Buy
Teladoc initiated with a Buy at Jefferies
Jefferies analyst Sean Dodge started Teladoc with a Buy rating and $40 price target. Member adds, increasing utilization and cross-selling should drive 20%-25% organic revenue growth over the next several years, Dodge tells investors in a research note. He notes that his firm survey data show nearly half of all providers intend to implement telehealth capabilities by 2021.
01/23/18
JPMS
01/23/18
NO CHANGE
Target $40
JPMS
Overweight
Teladoc selloff presents buying opportunity, says JPMorgan
JPMorgan analyst Lisa Gill says the ongoing weakness in shares of Teladoc represents a buying opportunity. The analyst sees potential upside to visits/revenue from heightened flu activity and keeps an Overweight rating on the shares with a $40 price target. Gill views the company's preliminary 2018 guidance as conservative.
EOG EOG Resources
$106.94

-2.55 (-2.33%)

01/04/18
BOFA
01/04/18
DOWNGRADE
Target $125
BOFA
Neutral
EOG Resources downgraded to Neutral on valuation at BofA/Merrill
As previously reported, BofA/Merrill downgraded EOG Resources to Neutral from Buy and increased its price target to $125 from $115. Analyst Doug Leggate said shares trade at a premium to peers and sees better risk/reward elsewhere.
01/23/18
FBCO
01/23/18
NO CHANGE
Target $126
FBCO
Neutral
EOG Resources price target raised to $126 from $106 at Credit Suisse
Credit Suisse analyst William Featherston raised his price target for EOG Resources to $126 from $106 on valuation. The analyst reiterates a Neutral rating on the shares.
01/08/18
ARGS
01/08/18
NO CHANGE
Target $133
ARGS
Buy
EOG Resources price target raised to $133 from $102 at Argus
Argus analyst Bill Selesky raises his price target on EOG Resources to $133, citing the management's focus on improving returns on invested capital, reducing operating costs, and maintaining a strong balance sheet. Selesky says the company "has become one of the industry's lowest-cost shale drillers", estimating up to 30% ROIC with crude oil trading as low as $40 per barrel. The analyst keeps his Buy rating on EOG Resources, raising his FY17 EPS view to 92c from 71c and 2018 to $2.27 from $1.58 amid the recent strength in crude oil prices and the company's well completions.
01/05/18
BARD
01/05/18
NO CHANGE
Target $122
BARD
Outperform
EOG Resources price target raised to $122 from $114 at Baird
Baird analyst Joseph Allman raised his price target on EOG Resources to $122 from $114 as he updated his model to reflect higher oil prices. In addition to higher oil prices, the analyst included the positive impact from the new tax law. Allman reiterated his Outperform rating on EOG Resources shares.
HTZ Hertz
$19.26

-0.76 (-3.80%)

01/18/18
01/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Walmart (WMT) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Matthew Fassler saying selling consumables to middle-income consumers in small markets remains a compelling strategic position. 2. Hertz (HTZ) upgraded to Outperform from Neutral at Macquarie with analyst Hamzah Mazari saying he is more bullish on 2018 rental car pricing given fleet cutting by Enterprise, the positive impact on corporate travel from tax reform, and the potential US infrastructure bill creating excess demand. For Hertz specifically. 3. Alarm.com (ALRM) upgraded to Buy from Hold at Jefferies analyst John DiFucci saying Alarm.com is at the forefront of the trend towards connected homes and devices. 4. PPL Corp. (PPL) upgraded to Buy from Hold at Deutsche Bank with analyst Jonathan Arnold saying the current valuation is "too cheap to ignore," and U.K. energy regulator Ofgem failing to implement a mid-period review of RIIO-ED1 offers "decent prospects for a near-term re-rating catalyst." 5. Fluor (FLR) upgraded to Outperform from Neutral at Credit Suisse with analyst Jamie Cook saying investors will gravitate back to Engineering & Construction stocks as fundamentals for the group are improving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/18
MACQ
01/18/18
UPGRADE
MACQ
Outperform
Hertz upgraded to Outperform on improving industry trends at Macquarie
Macquarie analyst Hamzah Mazari upgraded Hertz to Outperform and raised its price target to $30 from $26. Mazari is more bullish on 2018 rental car pricing given fleet cutting by Enterprise, the positive impact on corporate travel from tax reform, and the potential US infrastructure bill creating excess demand. For Hertz specifically, Mazari said expectations are low, investment spending is rolling off, and the industry is operating as a more "functional oligopoly."
12/01/17
MSCN
12/01/17
NO CHANGE
MSCN
Hertz mentioned positively at MScience
01/18/18
MACQ
01/18/18
UPGRADE
MACQ
Outperform
Hertz upgraded to Outperform from Neutral at Macquarie
CELG Celgene
$95.78

-0.71 (-0.74%)

02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/18
LEHM
02/13/18
UPGRADE
Target $105
LEHM
Overweight
Celgene upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Celgene to Overweight with an unchanged price target of $105. The analyst remains concerned about Revlimid concentration risk long-term, but says the current valuation largely reflects the risk. Since the highs in October 2017, the stock has dropped $55 per share, Meacham tells investors in a research note. He notes Celgene's risk/reward profile based on his net present value analysis yields an "attractive upside case."
02/09/18
PIPR
02/09/18
NO CHANGE
PIPR
Piper Jaffray reiterates Outperform on Crispr after CSO departure
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $39 price target on Crispr Therapeutics, despite Crispr trading down over 13% on news that Dr. Bill Lundberg is stepping down as Chief Scientific Officer and Celgene (CELG) has reduced its stake in the company to 6.1% from 8.0%. Tenthoff said he remains focused on Crispr's "therapeutic opportunity with first-in-man CTX001 Beta thalassemia and potentially sickle cell disease data this year."
01/29/18
WELS
01/29/18
NO CHANGE
Target $23
WELS
Outperform
Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$44.49

-0.775 (-1.71%)

12:44
07/15/18
07/15
12:44
07/15/18
12:44
Periodicals
Twitter suspends accounts linked to Russians indicted by Mueller, Reuters says »

Twitter has suspended two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 27

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:29
07/15/18
07/15
12:29
07/15/18
12:29
Periodicals
Trump says he will run for reelection, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:22
07/15/18
07/15
12:22
07/15/18
12:22
Periodicals
Airbus in talks for repeat Viva Aerobus jet order, Reuters says »

Airbus is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$350.81

4.79 (1.38%)

12:19
07/15/18
07/15
12:19
07/15/18
12:19
Periodicals
Boeing concerned about tariff talk, Reuters reports »

Boeing is concerned about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:17
07/15/18
07/15
12:17
07/15/18
12:17
Periodicals
President Trump calls EU a 'foe' on trade, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$203.32

1.29 (0.64%)

12:14
07/15/18
07/15
12:14
07/15/18
12:14
Hot Stocks
L3 Technologies appoints new SVP, Chief Global Business Development Officer »

L3 Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

0.43 (0.21%)

, TWTR

Twitter

$44.49

-0.775 (-1.71%)

13:27
07/14/18
07/14
13:27
07/14/18
13:27
Periodicals
Facebook, Alphabet to testify at U.S. House hearing, Reuters reports »

The U.S. House Judiciary…

FB

Facebook

$207.33

0.43 (0.21%)

TWTR

Twitter

$44.49

-0.775 (-1.71%)

GOOG

Alphabet

$1,188.81

4.94 (0.42%)

GOOGL

Alphabet Class A

$1,204.34

2.43 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

AAPL

Apple

$191.32

0.19 (0.10%)

, T

AT&T

$31.66

-0.56 (-1.74%)

13:06
07/14/18
07/14
13:06
07/14/18
13:06
Periodicals
Apple's next iPhone may be debut of eSIM, Barron's says »

Apple's (AAPL) next…

AAPL

Apple

$191.32

0.19 (0.10%)

T

AT&T

$31.66

-0.56 (-1.74%)

VZ

Verizon

$51.41

0.17 (0.33%)

S

Sprint

$5.66

(0.00%)

TMUS

T-Mobile

$61.68

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

AEP

American Electric

$70.37

-0.02 (-0.03%)

, NEE

NextEra Energy

$169.60

1.06 (0.63%)

12:57
07/14/18
07/14
12:57
07/14/18
12:57
Periodicals
Utility stocks worth a second look, Barron's says »

Utility stocks like…

AEP

American Electric

$70.37

-0.02 (-0.03%)

NEE

NextEra Energy

$169.60

1.06 (0.63%)

XEL

Xcel Energy

$46.26

-0.09 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

, CA

CA Technologies

$44.07

-0.08 (-0.18%)

12:50
07/14/18
07/14
12:50
07/14/18
12:50
Periodicals
Broadcom testing investors' faith, Barron's says »

For a while, shareholders…

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

CA

CA Technologies

$44.07

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$23.40

-0.84 (-3.47%)

, HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

12:16
07/14/18
07/14
12:16
07/14/18
12:16
Periodicals
Ackman might be making a comeback, Barron's says »

Bill Ackman's…

VRX

Valeant

$23.40

-0.84 (-3.47%)

HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

ARNC

Arconic

$17.39

0.08 (0.46%)

, APO

Apollo Global

$36.13

0.26 (0.72%)

08:41
07/14/18
07/14
08:41
07/14/18
08:41
Periodicals
Apollo, other PE firms express interest in Arconic, WSJ reports »

Arconic (ARNC) has…

ARNC

Arconic

$17.39

0.08 (0.46%)

APO

Apollo Global

$36.13

0.26 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PFE

Pfizer

$37.53

0.01 (0.03%)

, BABA

Alibaba

$190.03

-0.14 (-0.07%)

08:23
07/14/18
07/14
08:23
07/14/18
08:23
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

PFE

Pfizer

$37.53

0.01 (0.03%)

BABA

Alibaba

$190.03

-0.14 (-0.07%)

BIDU

Baidu

$267.20

-4.31 (-1.59%)

JD

JD.com

$38.27

-0.25 (-0.65%)

IQ

iQIYI

$33.92

-1.12 (-3.20%)

VIPS

Vipshop

$10.23

-0.09 (-0.87%)

NYT

New York Times

$25.60

-0.6 (-2.29%)

PLNT

Planet Fitness

$48.71

1.2 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

XYL

Xylem

$68.55

0.485 (0.71%)

, AQUA

Evoqua Water

$20.71

(0.00%)

04:55
07/14/18
07/14
04:55
07/14/18
04:55
Conference/Events
RBC Capital to hold a field trip »

Asia Water Sector Field…

XYL

Xylem

$68.55

0.485 (0.71%)

AQUA

Evoqua Water

$20.71

(0.00%)

DHR

Danaher

$99.25

-0.4 (-0.40%)

PNR

Pentair

$43.53

0.67 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 07

    Aug

HJLI

Hancock Jaffe Laboratories

$3.20

-0.025 (-0.78%)

18:20
07/13/18
07/13
18:20
07/13/18
18:20
Hot Stocks
Hancock Jaffe Laboratories names Bob Rankin as CFO, effective July 16 »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CKH

Seacor

$53.63

0.69 (1.30%)

, LPG

Dorian LPG

$7.92

0.115 (1.47%)

18:16
07/13/18
07/13
18:16
07/13/18
18:16
Hot Stocks
Seacor favors combination of Dorian LPG and BW LPG Limited »

Seacor (CKH) announced…

CKH

Seacor

$53.63

0.69 (1.30%)

LPG

Dorian LPG

$7.92

0.115 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:53
07/13/18
07/13
17:53
07/13/18
17:53
Hot Stocks
Senator Rubio says ZTE 'should be put out of business' »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TEVA

Teva

$23.29

-0.45 (-1.90%)

, NVS

Novartis

$78.78

-0.15 (-0.19%)

17:47
07/13/18
07/13
17:47
07/13/18
17:47
Hot Stocks
FDA announces voluntary recall of several medicines containing valsartan »

The U.S. Food and Drug…

TEVA

Teva

$23.29

-0.45 (-1.90%)

NVS

Novartis

$78.78

-0.15 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:26
07/13/18
07/13
17:26
07/13/18
17:26
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:25
07/13/18
07/13
17:25
07/13/18
17:25
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$7.49

0.09 (1.22%)

17:24
07/13/18
07/13
17:24
07/13/18
17:24
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

, XLU

Utilities SPDR

$52.56

0.04 (0.08%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
General news
Week ending ETF Scorecard: Industrials rebound into lead, Utilities lag »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

XLU

Utilities SPDR

$52.56

0.04 (0.08%)

IYR

DJ US Real Estate Index Fund

$81.37

-0.19 (-0.23%)

XLP

Consumer Staples Sector SPDR

$52.73

0.32 (0.61%)

XLY

Consumer Discretionary Sector SPDR

$112.62

0.27 (0.24%)

XLB

S&P Select Materials SPDR

$58.59

-0.02 (-0.03%)

XLF

Financial Select Sector

$26.96

-0.13 (-0.48%)

XLV

Health Care Select Sector SPDR

$87.44

0.18 (0.21%)

XLK

Technology Select Sector SPDR

$72.56

-0.07 (-0.10%)

XLI

Industrial Select Sector SPDR

$73.77

0.43 (0.59%)

GLD

SPDR Gold Trust

$117.60

-0.515 (-0.44%)

SLV

iShares Silver Trust

$14.88

-0.13 (-0.87%)

USO

United States Oil Fund

$14.47

0.085 (0.59%)

UNG

United States Natural Gas Fund

$22.40

-0.3 (-1.32%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.63

0.005 (0.01%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.76

0.16 (0.14%)

TLT

iShares 20+ Year Treasury Bond Fund

$122.74

0.33 (0.27%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.60

0.165 (0.16%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

0.025 (0.03%)

IWD

iShares Russell 1000 Value

$123.04

-0.07 (-0.06%)

IWF

iShares Russell 1000 Growth

$149.33

0.33 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$1.04

-0.015 (-1.42%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
Hot Stocks
CEL-SCI receives noncompliance letter from NYSE »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$53.47

-0.18 (-0.34%)

17:13
07/13/18
07/13
17:13
07/13/18
17:13
Hot Stocks
Yankees suspend relationship with Papa John's »

The New York Yankees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NCNA

NuCana

$24.00

-0.01 (-0.04%)

17:08
07/13/18
07/13
17:08
07/13/18
17:08
Hot Stocks
Breaking Hot Stocks news story on NuCana »

Christopher B. Wood…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.